Highlights Morphic Holding, Inc.

Equities

MORF

US61775R1059

Real-time Estimate Cboe BZX Other stock markets 01:36:16 2024-06-05 pm EDT			5-day change	1st Jan Change
32.3 ^USD	+5.85%		+7.67%	+12.22%

Jun. 04	Crystal Amber's Portfolio Company Wins US Regulatory Nod for Diabetes Device Study Amendment	MT
May. 21	Morphic Demonstrates Novel Real-Time Visualization of Small Molecule A4ß7 Inhibition of Gut-Trafficking Cells	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Morphic Demonstrates Novel Real-Time Visualization of Small Molecule A4ß7 Inhibition of Gut-Trafficking Cells	May. 21	CI
Morphic Holding, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Morphic Holding's Full Year 2023 Net Loss Widens, Collaboration Revenue Falls	Feb. 22	MT
Morphic Holding, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
North American Morning Briefing : Stock Futures -2-	Feb. 21	DJ
Morphic Ethical Equities Fund Buys Back Shares	Dec. 27	MT
Morphic Holding, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03	CI
Morphic Holding, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Morphic Holding, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Morphic Reports Positive Topline Results of the Emerald-1 Uc Main Cohort	23-04-25	CI
Morphic 2022 Loss Narrows, Revenue Rises	23-02-23	MT
MORPHIC HOLDING, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-02-23	AQ
Morphic Holding, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-23	CI
Morphic Starts Phase 2b Trial of MORF-057 in Ulcerative Colitis Patients	22-11-22	MT
Morphic Therapeutic AnnouncesInitiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis	22-11-22	CI
Morphic Holding Q3 Loss Widens as Revenue Declines	22-11-02	MT
Morphic Holding, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-02	CI
Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022	22-10-25	CI
Morphic Completes Enrollment in Ulcerative Colitis Trial Early	22-10-24	MT
Morphic Therapeutic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections	22-10-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Morphic Holding, Inc.

Equities

MORF

US61775R1059

Highlights

Filters